VICP · Vicapsys Life Sciences, Inc. · Executive Compensation
$0.50
At close · Nov 4
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jan 10, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern and to operate in the normal course of business within one year after the date that the financial statements are issued.”View the 10-Q filed Jan 10, 2025
Market Cap
$16.19M
Shares
32.37M
Volume · Nov 4
1400
Avg daily vol (23 sessions)
3964
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Richard Rosenblum | member of the Board | Appointed | 2022-09-28 |
| Charles "Charlie" Farrahar | member of the Board | Appointed | 2022-09-28 |
| Dr. Colleen Delaney | member of the Board | Appointed | 2022-09-28 |
| Michael Yurkowsky | member of the Board | Resigned | 2022-09-28 |
| John Potts | member of the Board | Resigned | 2022-09-28 |
Leadership
- Federico Pier CEO
- Charles "Charlie" Farrahar Board Member
- Dr. Colleen Delaney Board Member
- Richard Rosenblum Board Member